PUBLISHER: TechNavio | PRODUCT CODE: 2109451
PUBLISHER: TechNavio | PRODUCT CODE: 2109451
Global Neuromuscular Disease Therapeutics Market 2026-2030
The global neuromuscular disease therapeutics market is forecasted to grow by USD 13094.5 mn during 2025-2030, accelerating at a CAGR of 12.9% during the forecast period. The report on the global neuromuscular disease therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of neuromuscular disorders and expanding molecular diagnostics, accelerating innovations in nucleic acid-based and gene replacement therapies, favorable regulatory frameworks and orphan drug designations.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 12% |
| CAGR | 12.9% |
| Incremental Value | $13094.5 mn |
Technavio's global neuromuscular disease therapeutics market is segmented as below:
By End-User
- Hospitals
- Clinics
- Others
By Type
- Biologics
- Small molecules
By Disease Type
- SMA
- Myasthenia gravis
- DMD
- ALS
- Others
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the paradigm shift toward single-dose curative gene replacement and gene-editing modalities as one of the prime reasons driving the global neuromuscular disease therapeutics market growth during the next few years. Also, exponential adoption of decentralized care and direct-to-patient home administration models and integration of next-generation sequencing and ai-driven early screening protocols will lead to sizable demand in the market.
The report on the global neuromuscular disease therapeutics market covers the following areas:
- Global neuromuscular disease therapeutics market sizing
- Global neuromuscular disease therapeutics market forecast
- Global neuromuscular disease therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global neuromuscular disease therapeutics market vendors that include AbbVie Inc., Amicus Therapeutics Inc., argenx SE, Astellas Pharma Inc., AstraZeneca Plc, Biogen Inc., Catalyst Pharmaceuticals Inc., Corium Inc., F. Hoffmann La Roche Ltd., Grifols SA, Ionis Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corp., Novartis AG, NS Pharma, Inc., PTC Therapeutics Inc., Sanofi SA, Sarepta Therapeutics Inc., Takeda Pharmaceutical Ltd., UCB SA. Also, the global neuromuscular disease therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Market Segmentation by Disease Type
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Neuromuscular Disease Therapeutics Market 2020 - 2024
- Historic Market Size - Data Table on Global Neuromuscular Disease Therapeutics Market 2020 - 2024 ($ million)
- 5.2 End-user segment analysis 2020 - 2024
- Historic Market Size - End-user Segment 2020 - 2024 ($ million)
- 5.3 Type segment analysis 2020 - 2024
- Historic Market Size - Type Segment 2020 - 2024 ($ million)
- 5.4 Disease Type segment analysis 2020 - 2024
- Historic Market Size - Disease Type Segment 2020 - 2024 ($ million)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
- 5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on global neuromuscular disease therapeutics market
- 6.2 Impact of geopolitical conflicts on global neuromuscular disease therapeutics market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by End-user
- 8.1 Market segments
- 8.2 Comparison by End-user
- 8.3 Hospitals - Market size and forecast 2025-2030
- 8.4 Clinics - Market size and forecast 2025-2030
- 8.5 Others - Market size and forecast 2025-2030
- 8.6 Market opportunity by End-user
- Market opportunity by End-user ($ million)
9 Market Segmentation by Type
- 9.1 Market segments
- 9.2 Comparison by Type
- 9.3 Biologics - Market size and forecast 2025-2030
- 9.4 Small molecules - Market size and forecast 2025-2030
- 9.5 Market opportunity by Type
- Market opportunity by Type ($ million)
10 Market Segmentation by Disease Type
- 10.1 Market segments
- 10.2 Comparison by Disease Type
- 10.3 SMA - Market size and forecast 2025-2030
- 10.4 Myasthenia gravis - Market size and forecast 2025-2030
- 10.5 DMD - Market size and forecast 2025-2030
- 10.6 ALS - Market size and forecast 2025-2030
- 10.7 Others - Market size and forecast 2025-2030
- 10.8 Market opportunity by Disease Type
- Market opportunity by Disease Type ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
- 12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 UK - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
- 12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 China - Market size and forecast 2025-2030
- 12.5.2 Japan - Market size and forecast 2025-2030
- 12.5.3 India - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Taiwan - Market size and forecast 2025-2030
- 12.5.6 Singapore - Market size and forecast 2025-2030
- 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Australia - Market size and forecast 2025-2030
- 12.6.2 Brazil - Market size and forecast 2025-2030
- 12.6.3 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.4 Argentina - Market size and forecast 2025-2030
- 12.6.5 South Africa - Market size and forecast 2025-2030
- 12.6.6 UAE - Market size and forecast 2025-2030
- 12.6.7 New Zealand - Market size and forecast 2025-2030
- 12.6.8 Turkey - Market size and forecast 2025-2030
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Rising prevalence of neuromuscular disorders and expanding molecular diagnostics
- Accelerating innovations in nucleic acid-based and gene replacement therapies
- Favorable regulatory frameworks and orphan drug designations
- 13.2 Market challenges
- Exorbitant financial burdens and restrictive reimbursement pathways
- Patient recruitment bottlenecks and intricate clinical trial frameworks
- Manufacturing scale-up constraints and specialized logistics infrastructure
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- Paradigm shift toward single-dose curative gene replacement and gene-editing modalities
- Exponential adoption of decentralized care and direct-to-patient home administration models
- Integration of next-generation sequencing and AI-driven early screening protocols
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 AbbVie Inc.
- AbbVie Inc. - Overview
- AbbVie Inc. - Business segments
- AbbVie Inc. - Key news
- AbbVie Inc. - Key offerings
- AbbVie Inc. - Segment focus
- SWOT
- 15.5 argenx SE
- argenx SE - Overview
- argenx SE - Product / Service
- argenx SE - Key offerings
- SWOT
- 15.6 Astellas Pharma Inc.
- Astellas Pharma Inc. - Overview
- Astellas Pharma Inc. - Product / Service
- Astellas Pharma Inc. - Key news
- Astellas Pharma Inc. - Key offerings
- SWOT
- 15.7 AstraZeneca Plc
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Business segments
- AstraZeneca Plc - Key news
- AstraZeneca Plc - Key offerings
- AstraZeneca Plc - Segment focus
- SWOT
- 15.8 Biogen Inc.
- Biogen Inc. - Overview
- Biogen Inc. - Product / Service
- Biogen Inc. - Key offerings
- SWOT
- 15.9 Corium Inc.
- Corium Inc. - Overview
- Corium Inc. - Product / Service
- Corium Inc. - Key offerings
- SWOT
- 15.10 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 15.11 Grifols SA
- Grifols SA - Overview
- Grifols SA - Business segments
- Grifols SA - Key offerings
- Grifols SA - Segment focus
- SWOT
- 15.12 Ionis Pharmaceuticals Inc.
- Ionis Pharmaceuticals Inc. - Overview
- Ionis Pharmaceuticals Inc. - Product / Service
- Ionis Pharmaceuticals Inc. - Key news
- Ionis Pharmaceuticals Inc. - Key offerings
- SWOT
- 15.13 Mitsubishi Tanabe Pharma Corp.
- Mitsubishi Tanabe Pharma Corp. - Overview
- Mitsubishi Tanabe Pharma Corp. - Product / Service
- Mitsubishi Tanabe Pharma Corp. - Key offerings
- SWOT
- 15.14 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 15.15 NS Pharma, Inc.
- NS Pharma, Inc. - Overview
- NS Pharma, Inc. - Product / Service
- NS Pharma, Inc. - Key offerings
- SWOT
- 15.16 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
- 15.17 Sarepta Therapeutics Inc.
- Sarepta Therapeutics Inc. - Overview
- Sarepta Therapeutics Inc. - Product / Service
- Sarepta Therapeutics Inc. - Key offerings
- SWOT
- 15.18 Takeda Pharmaceutical Ltd.
- Takeda Pharmaceutical Ltd. - Overview
- Takeda Pharmaceutical Ltd. - Business segments
- Takeda Pharmaceutical Ltd. - Key news
- Takeda Pharmaceutical Ltd. - Key offerings
- Takeda Pharmaceutical Ltd. - Segment focus
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
